anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Seroma after breast cancer surgery is a frequent entity; therefore, different products have been described in literature with the aim to reduce it. The most studied ones have been the sealants products, being tested with aspirative drains. Symptomatic seroma represents the 19% after axillary lymphadenectomy without drains. The aim of this study is to analyze the effect of a sealant in the seroma control after axillary lymphadenectomy without drains and identify the risk factors related to symptomatic seroma.
METHODS: This is a prospective, multicenter, international, and randomized clinical trial. Patients undergoing conservative surgery and axillary lymphadenectomy for breast cancer will be randomized to control group (lymphadenectomy without sealant) or interventional group (lymphadenectomy with sealant Glubran 2®). In any of the study groups, drains are placed. Patients who received neoadjuvant treatment are included. Measurements of the study outcomes will take place at baseline; at 7, 14, and 30 days post-surgery; and at 6-12 months. The primary outcome is symptomatic seroma. Secondary outcomes are seroma volume, morbidity, quality of life, and lymphedema.
DISCUSSION: Several studies compare the use of sealant products in axillary lymphadenectomy but generally with drains. We would like to demonstrate that patients who underwent axillary lymphadenectomy could benefit from an axillary sealant without drains and reduce axillary discomfort while maintaining a good quality of life. Assessing the relationship between axillary volume, symptoms, and related risk factors can be of great help in the control of seroma in patients who received breast cancer surgery.
TRIAL REGISTRATION: ClinicalTrials.gov, NCT05280353. Registration date 02 August 2022.
The investigators will enroll 55 Veterans with chronic subcortical stroke in the 12-week HIIT intervention, with the expectation that 48 participants (85%) will complete the entire program. In our experience, 65% of participants will respond to the HIIT intervention, resulting in an estimated 31 responders and 17 resistors. Each chronic subcortical stroke participant will be asked to participate in the HIIT study protocol. Classification of resistor or responder: A responder to the 12-week HIIT intervention will be defined as a participant who increases their walking speed to greater than 0.6 m/s. A resistor to the intervention will be defined as a participant who does not increase their walking speed to greater than 0.6 m/s.
The GENOTROPIN 5 and 12 mg cartridges are color-coded to help ensure proper use with the GENOTROPIN PEN delivery device. The 5 mg cartridge has a green tip to match the green pen window on the Pen 5, while the 12 mg cartridge has a purple tip to match the purple pen window on the Pen 12.

Parenteral drug products should always be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. GENOTROPIN MUST NOT BE INJECTED if the solution is cloudy or contains particulate matter. Use it only if it is clear and colorless.

GENOTROPIN may be given in the thigh, buttocks, or abdomen; the site of SC injections should be rotated daily to help prevent lipoatrophy.
A mechanism is provided in a data processing system to implement localized device specific limitations on access to patient medical information. An authorizing device receives a request from a requestor device via a dose proximity communication protocol requesting to access an electronic medical record (EMR) associated with a patient. The authorizing device receives user input via a user interface specifying conditions for permitting access to the EMR. The authorizing device transmits an access authorization request to a patient registry system requesting the patient registry system to provide access to the EMR associated with the patient in accordance with the conditions for permitting access specified by the user input. The patient registry system generates a temporary access data structure based on the specified conditions. The patient registry system processes a subsequent request from the requestor device to access the EMR in accordance with the temporary access data structure.
Lung ultrasound (LUS) is an effective tool for diagnosing acute heart failure (AHF). However, several imaging protocols currently exist and how to best use LUS remains undefined. We aimed at developing a lung ultrasound-based model for AHF diagnosis using machine learning. Random forest and decision trees were generated using the LUS data (via an 8-zone scanning protocol) in patients with acute dyspnea admitted to the Emergency Department (PLUME study, N = 117) and subsequently validated in an external dataset (80 controls from the REMI study, 50 cases from the Nancy AHF cohort). Using the random forest model, total B-line sum (i.e., in both hemithoraces) was the most significant variable for identifying AHF, followed by the difference in B-line sum between the superior and inferior lung areas. The decision tree algorithm had a good diagnostic accuracy [area under the curve (AUC) = 0.865] and identified three risk groups (i.e., low 24%, high 70%, and very high-risk 96%) for AHF. The very high-risk group was defined by the presence of 14 or more B-lines in both hemithoraces while the high-risk group was described as having either B-lines mostly localized in superior points or in the right hemithorax. Accuracy in the validation cohort was excellent (AUC = 0.906). Importantly, adding the algorithm on top of a validated clinical score and classical definition of positive LUS scanning for AHF resulted in a significant improvement in diagnostic accuracy (continuous net reclassification improvement = 1.21, P < 0.001). Our simple lung ultrasound-based machine learning algorithm features an excellent performance and may constitute a validated strategy to diagnose AHF.
The invention relates to a preparation method for a traditional Chinese medicine lotion for treatment of liver depression fire formation-type closed fractures, and belongs to the technical field of traditional Chinese medicine preparation methods. At present, treatment of liver depression fire formation-type closed fractures generally uses western medicines. A disadvantage of using western medicines is that certain side effects exist. The technical solution of the invention includes: taking turmeric root-tuber, fruit of fiverleaf akebia, lunate peltate sundew herb, semen celosiae, flos buddlejae, flos eriocauli, herb of ramose scouring rush, chrysanthemum, peppermint, cicada slough, elephant skin, kadsura root-bark, northeast giant black chafer, flower of garden balsam, leech, fructus polygoni orientalis, humifuse euphorbia herb, yanhusuo, pyrite, diverse wormwood herb, safflower, rhododendron, lignum sappan, chinese honeylocust spine, myrrh, suberect spatholobus stem, frankincense, hiraute shiny bugleweek herb, tamariskoid spikemoss herb, acronychia pedunculata, polygonum paleaceum wall, motherwort fruit, winnged euonymus twig, pummelo fruit, and liquorice root; soaking the above 35 traditional Chinese medicines in water; decocting by slow fire; and filtering to remove dregs. The left medicine liquid is the traditional Chinese medicine lotion for the treatment of liver depression fire formation-type closed fractures. The lotion has the advantages that the traditional Chinese medicine liquid is fewer in side effects, short in treatment courses, and high in cure rate.
Acute otitis media (OM) and OM with effusion are common childhood diseases. Nontypeable Haemophilus influenzae (NTHi) is a leading cause of OM and respiratory infections in older individuals. Currently, there is no vaccine for NTHi infection. Studies indicate that serum bactericidal antibodies are associated with protection from NTHi infection. We predict that serum antibodies with bactericidal activity to the lipooligosaccharide (LOS), a major surface antigen and virulence factor of NTHi, will confer immunity to this pathogen. LOS of NTHi is too toxic to administer to humans and detoxified LOS (dLOS) is not immunogenic, probably due to its low molecular weight. In order to improve its immunogenicity, the dLOS was convalently bound to tetanus toxoid (TT) using a clinically relevant scheme of vaccination, elicited bactericidal antibodies to LOS in an in vivo model. This investigational vaccine also showed protection against infection in a chinchilla otitis media model. We propose to evaluate the safety and immunogenicity of this dLOS-TT vaccine in adults (Phase I). Our goal is to develop a vaccine for OM and respiratory infections caused by NTHi.
This is a randomized controlled trial. Patients will be randomized to have their knee implanted using either the patient-specific custom cutting blocks or the regular instrumentation system. Functional and radiographic outcomes will be assessed in a blinded fashion. The Smith and Nephew Legion Primary® total knee system will be used in both groups; this is an implant with a good long term track record based on the Genesis II design. All surgeons have used and are familiar with the regular instrumentation. They will be instructed in the use of the patient-specific custom cutting blocks prior to study initiation.
The inventions disclosed herein include methods, systems, and tools for use in processing prescriptions. Among the benefits of these methods, systems, and tools are promotion of efficiency in filling prescriptions and reduction of errors. A heightened analysis element may be established that alerts a pharmaceutical professional to a particular component of a prescription (a prescription element) for special attention. An insignificant differences notice may de-emphasize certain prescription elements to inform a pharmaceutical professional that the information of such prescription elements is less critical. Methods of the present invention may be used to designate a prescription as a renewal, partial renewal, or partially equivalent renewal. The disclosed inventions include methods of creating and/or using such heightened analysis elements, insignificant differences notices, and/or designation of a prescription as a renewal, partial renewal, or partially equivalent renewal.
Persons with serious mental illness (SMI) die on average 10-15 years earlier than those in the general population. Smoking is the strongest risk factor for their elevated mortality. Helping SMI smokers to quit is an urgent and unmet need. The hospital is an optimal setting to provide smoking cessation services. Hospital admissions for SMI are common with more than 1.2 million inpatient stays for schizophrenia and mood disorders per year in the US. Hospitalized patients experience required abstinence, are available for counseling, and can try cessation medications in a supportive setting. The challenge is how to engage SMI patients in cessation services post-discharge. An easy-to-access digital intervention is a scalable and sustainable way to bridge the inpatient-to-outpatient gap and to promote sustained abstinence. Digital interventions can deliver all elements of cessation treatment and yield quit rates comparable to face to face and telephonic interventions. SMI patients use and benefit from technology-based interventions but currently there is no digital smoking cessation program addressing their needs. This R34 application will adapt a proven digital intervention, BecomeAnEX (EX), developed and run by Truth Initiative for over 10 years. Its core components are real-time one on one coaching via live chat, nicotine replacement therapy decision support and delivery, personalized quit plans, a large online social network for peer support, a robust and fully integrated text message program, and tailored email messaging. Adaptation will ensure that EX addresses the specific challenges of SMI smokers and is in line with principles of mental health recovery. In Aim 1 the investigators will develop and obtain preliminary feedback about EX-SMI, a version of EX adapted for SMI patients. A priori target mechanisms are motivation, abstinence self-efficacy, and cravings. In Aim 2 the investigators will conduct a one-arm pilot trial and obtain feedback from 20 SMI smokers recruited during psychiatric hospitalization and followed up at 2-weeks and 1-month post-discharge. Feasibility and acceptability will be assessed via participant feedback regarding their intervention experience, changes in motivation, self-efficacy and cravings, and automated tracking data on EX-SMI use post-discharge. In Aim 3, 90 SMI smokers recruited during psychiatric hospitalization will be randomized to usual care or to a revised version of EX-SMI and followed for 3 months after the hospital stay. The investigators will compare the feasibility/acceptability of EX-SMI, measure intervention impact on target mechanisms, and obtain initial estimates of efficacy on 7-day point prevalence abstinence. This pilot work directly addresses priorities of this RFA in refining and optimizing an efficacious intervention for a new target population. Ultimately, this program of research could have a powerful public health impact by increasing smoking cessation among persons with SMI.
Background: Abdominal fat accumulation is a known risk factor for cardiometabolic diseases and mortality, particularly in women. This study aimed to compare the prevalence of abdominal obesity and its associated factors in 2003 and 2015. Methods: Two cross-sectional, population-based surveys were conducted, including representative and independent samples of adult women 20-60 years of age residing in the urban area of São Leopoldo/RS municipality in 2003 (n = 981) and 2015 (n = 984). Abdominal obesity was assessed using waist circumference, with a measurement of ≥88 cm indicating its presence. Factors, such as demographics, socioeconomic status, reproductive health, family history, morbidity, and behavioral characteristics, were studied. Poisson regression was used to assess the associations. Results: The mean age of individuals in the samples was 38.5 years (±11.1 years) and 40.3 years (±11.4 years) in 2003 and 2015, respectively. The prevalence of abdominal obesity doubled from 23.3% (95% confidence interval [CI]: 20.7-26.0) in 2003 to 46.9% (95% CI: 43.7-50.0) in 2015. After adjustment, the prevalence of abdominal obesity remained higher in both 2003 and 2015 with increasing age, low family income, higher number of pregnancies, earlier age at menarche, and presence of a family history of obesity in the father and mother and in women with a history of hypertension. Conclusions: This study demonstrates an increase in the prevalence of abdominal obesity in women between 2003 and 2015 and highlights the sociodemographic, reproductive, family history, and comorbidity aspects associated with its occurrence.
The inspiratory muscle training protocol (IMT) high intensity is achieved with a device with linear load pressure (POWERbreathe Plus Light Resistance®, SP, BR) that allows loads up to -90cmH2O. IMT is performed for 36 sessions (12 weeks) with weekly frequency of three times a week under supervision prior to the cardiac rehabilitation. The training protocol consists of five series with 10 repetitions each set until the 8th week with increase in the number of sets of repetitions of the 8th to 12th week, with two minutes or according to patient feedback using the modified Borg scale . Aerobic training lasts 40 minutes (5 minutes heating 30 minute workout and 5 minutes desaqueciemento. During training vital signs such as heart rate, blood pressure (BP) and peripheral oxygen saturation (SpO2) are evaluated and the feeling of effort the patient should not exceed the level of 8 according to the modified Borg scale.
The invention provides a tumor-targeted DNA fluorescent probe and a preparation method and application thereof, and relates to the technical field of biochemical nano materials. The tumor targeting DNA fluorescent probe has stable property and good biocompatibility. The micromolecular fluorescent dye Cy5.5 is used as a targeting molecule, has low cost and targeting property on various tumors, and therefore, can be used for diagnosing the tumors through the fluorescent property of Cy5.5. It can also be used as a drug carrier, so that the antitumor drug has targeting property, and the utilization rate and the treatment effective rate of the antitumor drug are improved. The tumor-targeted DNA fluorescent probe provided by the invention can integrate the diagnosis and treatment of tumors into a whole, and has wider application. In addition, the cyanine dye Cy5.5 can generate active oxygen with cytotoxicity under laser irradiation, thereby realizing the effect of enhancing the chemotherapy effect.
The present invention is to solve the problems of the existing glove with poor comfortability and finger flexibility influence, and the present invention provides a pair of bactericidal skin lotion transparent gloves which contain chitin salt. The present invention relates to aqueous salt solution which comprises chitin which is neutralized with acid, the range of the deacetylation degree of the chitin is from 50 to 99%, the range of the molecular weight is from 10 to 2000 thousand, and the range of the weight percentage content is from 0.1 to 10%. The acid solution which is used for neutralizing the chitin is inorganic or organic acid solution, and the range of the weight percentage concentration of the acid solution is from 0.1 to 10%. According to the purpose requirements, safe antibiotic bacteriostasis substances are also added, such as 0.01 to 10% of iodophor or chlorhexidine, etc. Additive with other efficiencies are also added, such as plasticizing agent, compound perfume, spice, etc. When the solution is smeared on hands of a human body, a layer of protection film which is appressed with the skin is formed quickly after air drying. The chitin is proved to have excellent natural characteristics of biocompatibility, nontoxicity, germ resistance, bacteriostasis, etc. The chitin which forms a film have the functions of removing oily soil, shrinking pores, removing spots and pox, keeping skin moisture, delaying skin ageing, etc.
The Patients enrolled will be sequentially assigned to the corresponding dose level, BHP01 was administered intravenous infusion at different cell dose levels. The patients were received multiple-dose infusion according to investigator's evaluation.
Immune checkpoint proteins (ICPs) play a major role in a patient's immune response against cancer. Tumour cells usually express those proteins to communicate with immune cells as a process of escaping the anti-cancer immune response. Detecting the major functional immune checkpoint proteins present on cancer cells (such as circulating tumor cells or CTCs) and examining the heterogeneity in their expression at the single-cell level could play a crucial role in both cancer diagnosis and the monitoring of therapy. In this study, we develop a mesoporous gold biosensor to precisely assess ICP heterogeneity in individual cancer cells within a lung cancer model. The platform utilizes a nanostructured mesoporous gold surface to capture CTCs and a Surface Enhanced Raman Scattering (SERS) readout to identify and monitor the expression of key ICP proteins (PD-L1, B7H4, CD276, CD80) in lung cancer cells. The homogeneous and abundant pores in mesoporous 3D gold nanostructures enable increased antibody loading on-chip and an enhanced SERS signal, which are key to our single cell capture, and accurate analysis of ICPs in cancer cells with high sensitivity. Our lung cancer cell line model data showed that our method can detect single cells and analyse the expression of four lung cancer associated ICPs on individual cell surfaces during treatment. To show the potential of our mesoporous gold biosensor in analysing clinical samples, we tested 9 longitudinal Peripheral Blood Mononuclear Cells (PBMC) samples from lung cancer patient before and after therapy. Our mesoporous biosensor successfully captured single CTCs and found that the expression of ICPs in CTCs is highly heterogeneous in both pre-treatment and treated PBMC samples isolated from lung cancer patient blood. We suggest that our findings will help clinicians in selecting the most appropriate therapy for patients.
The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
<P>PROBLEM TO BE SOLVED: To provide a highly safe antitumor agent having excellent antitumor effects.  <P>SOLUTION: The antitumor agent is characterized as comprising an acidic xylooligosaccharide having a uronic acid residue in the xylooligosaccharide molecule. The acidic xylooligosaccharide is a mixed composition of oligosaccharides having different degrees of polymerization of xylose. The average degree of polymerization is preferably 2.0-15.0. The acidic xylooligosaccharide is preferably obtained by enzymically and/or physico-chemically treating a lignocellulose material, affording a complex of a xylooligosaccharide component with a lignin component, then carrying out an acid hydrolysis treatment of the resultant complex, providing a xylooligosaccharide mixture and separating the xylooligosaccharide having at least one or more uronic acid residues in one molecule as a side chain from the resultant xylooligosaccharide mixture.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Imbalance between excitation and inhibition is an important cause of epilepsy. Salt-inducible kinase 1 (SIK1) gene mutation can cause epilepsy. In this study, we first found that the expression of SIK3 is increased after epilepsy. Furthermore, the role of SIK3 in epilepsy was explored. In cultured hippocampal neurons, we used Pterosin B, a selective SIK3 inhibitor that can inhibit epileptiform discharges induced by the convulsant drug cyclothiazide (a positive allosteric modulator of AMPA receptors, CTZ). Knockdown of SIK3 inhibited epileptiform discharges and increased the amplitude of miniature inhibitory postsynaptic currents (mIPSCs). In mice, knockdown of SIK3 reduced epilepsy susceptibility in a pentylenetetrazole (a GABAA receptor antagonist, PTZ) acute kindling experiment and increased the expression of GABAA receptor α1. In conclusion, our results suggest that blockade or knockdown of SIK3 can inhibit epileptiform discharges and that SIK3 has the potential to be a novel target for epilepsy treatment.